Evidence map›Paper›PMID 37886506›Full record

ArticleResearch square2023

Advancing Tau-PET quantification in Alzheimer's disease with machine learning: introducing THETA, a novel tau summary measure.

Robel K Gebre, Alexis Moscoso Rial, Sheelakumari Raghavan, Heather J Wiste, Kohl L Johnson Sparrman, Fiona Heeman, Alejandro Costoya-Sánchez, Christopher G Schwarz, Anthony J Spychalla, Val J Lowe and 7 more

Abstract readPreprint
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Robel K GebreDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-5746-0994
Alexis Moscoso RialDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0003-0170-036X
Sheelakumari RaghavanDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Heather J WisteDepartment of Qualitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Kohl L Johnson SparrmanDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Fiona HeemanDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Alejandro Costoya-SánchezUniversidade de Santiago de Compostela, Santiago de Compostela, Spain.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-1466-8357
Anthony J SpychallaDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Val J LoweDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0002-6544-066X
Ronald C PetersenDepartment of Qualitative Health Sciences, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-8178-6601
Michael SchöllDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-7800-1781
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0001-7916-622X
Prashanthi VemuriDepartment of Radiology, Mayo Clinic, Rochester, MN 55905, USA.ORCID 0000-0003-4286-0589
Alzheimer’s Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI SCHINDLER, SUZANNE ELIZABETH · 2005 to 2025
$49.5M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI BU, GUOJUN · 1999 to 2018
$36.9M
Research Education ComponentP30AG066444 · NIA · WASHINGTON UNIVERSITY · PI DAVID M. HOLTZMAN · 2020 to 2026
$28.7M
THE XNAT IMAGING INFORMATICS PLATFORMR01EB009352 · NIBIB · WASHINGTON UNIVERSITY · PI Daniel Scott Marcus · 2009 to 2026
$9.3M
Investigating Resistance and Resilience Mechanisms in Alzheimer’s DiseaseR01AG056366 · NIA · MAYO CLINIC ROCHESTER · PI PRASHANTHI VEMURI · 2017 to 2026
$7.0M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
MarkVCID Validation in the General CommunityUF1NS125417 · NINDS · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C, VEMURI, PRASHANTHI · 2021 to 2023
$6.1M
NCATS NIH HHS UL1 TR000448NCRR NIH HHS C06 RR018898NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P30 AG066444NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG056366NIA NIH HHS R21 AG058738NIA NIH HHS R33 AG058738NIA NIH HHS R37 AG011378NIA NIH HHS RF1 AG069052NIA NIH HHS U01 AG006786NIA NIH HHS U01 AG024904NIBIB NIH HHS R01 EB009352NINDS NIH HHS R01 NS097495NINDS NIH HHS UF1 NS125417
6 · The paper itself

Abstract

Alzheimer's disease (AD) exhibits spatially heterogeneous 3R/4R tau pathology distributions across participants, making it a challenge to quantify extent of tau deposition. Utilizing Tau-PET from three independent cohorts, we trained and validated a machine learning model to identify visually positive Tau-PET scans from regional SUVR values and developed a novel summary measure, THETA, that accounts for heterogeneity in tau deposition. The model for identification of tau positivity achieved a balanced test accuracy of 95% and accuracy of ≥87% on the validation datasets. THETA captured heterogeneity of tau deposition, had better association with clinical measures, and corresponded better with visual assessments in comparison with the temporal meta-region-of-interest Tau-PET quantification methods. Our novel approach aids in identification of positive Tau-PET scans and provides a quantitative summary measure, THETA, that effectively captures the heterogeneous tau deposition seen in AD. The application of THETA for quantifying Tau-PET in AD exhibits great potential.

Identifiers

PMID37886506
PMCPMC10602128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.